Suchergebnisse - (Subject:"CK")

PubPharm (5.078)

1

Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer : recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines

enthalten in: Breast cancer (Tokyo, Japan) | 2024

von Hattori, M. | Honma, N. | Nagai, S. | +18

2

A Multifunctional Bimetallic Nanoplatform for Synergic Local Hyperthermia and Chemotherapy Targeting HER2-Positive Breast Cancer

enthalten in: Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2024

von Zhao, L. | Chang, F. | Tong, Y. | +5

3

Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H2Mab-250/H2CasMab-2 for Breast Cancers

enthalten in: Monoclonal antibodies in immunodiagnosis and immunotherapy | 2024

von Kaneko, M. | Suzuki, H. | Kato, Y.

ErratumIn: Monoclon Antib Immunodiagn Immunother. 2024 Apr 16;:. - PMID 38625004

4

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain) : a randomised, open-label, phase 2 trial

enthalten in: Lancet (London, England) | 2024

von Pérez-García, J. | Cortés, J. | Ruiz-Borrego, M. | +27

5

Safe de-escalation of chemotherapy in HER2-positive early breast cancer

enthalten in: Lancet (London, England) | 2024

von Earl, H.

6

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01) : primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

enthalten in: The Lancet. Oncology | 2024

von Smit, E. | Felip, E. | Uprety, D. | +17

7

Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet

enthalten in: Anticancer research | 2024

von Sato, M. | Han, Q. | Mori, R. | +7

8

Fe3O4-Cy5.5-trastuzumab magnetic nanoparticles for magnetic resonance/near-infrared imaging targeting HER2 in breast cancer

enthalten in: Biomedical materials (Bristol, England) | 2024

von Yin, Q. | Gao, X. | Zhang, H. | +5

9

Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)

enthalten in: Zhonghua zhong liu za zhi [Chinese journal of oncology | 2024

von Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group

10

NSABP FB-10 : a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

enthalten in: Breast cancer research : BCR | 2024

von Jacobs, S. | Wang, Y. | Abraham, J. | +18

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[508]